

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041783 A1

(51) International Patent Classification⁷: C07D 209/88

MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/SK2003/000020

(22) International Filing Date:
4 November 2003 (04.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PP 1595-2002 8 November 2002 (08.11.2002) SK

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *of inventorship (Rule 4.17(iv)) for US only*

(71) Applicant (*for all designated States except US*): ZENTIVA, A.S. [SK/SK]; Nitrianska 100, 920 27 Hlohovec (SK).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HERCEK, Richard [SK/SK]; Michalská 7, 920 01 Hlohovec (SK). SKODA, Alojz [SK/SK]; Michalská 10, 920 01 Hlohovec (SK). PROKSA, Bohumil [SK/SK]; Vinohradská 1, 920 01 Hlohovec (SK).

(74) Agent: NEUSCHL, Jozef; Rott, Ruzicka & Guttmann, Patentová, známková a právna kancelária, v.o.s., Pionierska 15, 831 02 Bratislava (SK).

Published:


— *with international search report*

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR PREPARATION OF CARVEDILOL

(57) Abstract: The invention solves a new method of preparation of Carvedilol for pharmaceutical use. In the synthesis of Carvedilol a reaction of 4-(oxirane-2-ylmethoxy)-9H-arbazole (II) with 2-(2-methoxyphenoxy)ethylamine salts (IV) in the presence of a base, in an alcohol having the number of carbons C2 to C5 as a solvent, at an elevated temperature, is used. After processing of the crude reaction mixture crude Carvedilol is obtained, which is purified by crystallization from ethylacetate with an addition of activated carbon and the final substance is formulated by crystallization from ethylacetate.



WO 2004/041783 A1


PROCESS FOR PREPARATION OF CARVEDILOL

Technical Field


This invention belongs to the field of the pharmaceutical production and relates to synthesis and purification of the active substance Carvedilol.

Background Art

Carvedilol, (\pm) 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)-ethyl]-amino]-2-propanol of structure I, is a combined α - and β -adrenolytic with vasodilating activity.



According to DE 2815926 (US 4,503,067) Carvedilol is prepared by the reaction of 4-(oxirane-2-ylmethoxy)-9H-carbazole (II) with 2-(2-methoxyphenoxy)ethylamine (III).



By the method described, Carvedilol is prepared in low yields, moreover contaminated with the bis-derivative. This problem is solved by the method according to EP 918 055, in which 4-(oxirane-2-ylmethoxy)-9H-carbazole (II) is coupled with N-benzylated 2-(2-methoxyphenoxy)ethylamine; by this method creation of bis-derivative is minimized and the yield of Carvedilol is increased, but a disadvantage of this method is introducing of an additional step – hydrogenolytic removal of the protective benzyl group on a palladium catalyst.

Another method of decreasing the amount of the bis-derivative and thus increasing the yield of the product in the process of preparation of Carvedilol is described in WO 0200216, wherein an epoxide (II) reacts with an amine (III) in a solvent or without any solvent, the product being isolated after the reaction in the form of Carvedilol hydrochloride hydrate from the reaction mixture after adding water, ethylacetate and diluted hydrochloric acid.

All the abovementioned methods of preparation of Carvedilol use, as one of the starting materials, the amine base (III), or its N-benzylated derivative, which have low stability - they are subject to decomposition in contact with air and light. The abovementioned disadvantages are solved by the method of this invention.

Disclosure of Invention

In the preparation of Carvedilol according to this invention 4-(oxirane-2-ylmethoxy)-9H-carbazole (II) reacts with salts of 2-(2-methoxyphenoxy)ethylamine (III), which can contain 0 to 10 % water, in the presence of a base in an organic solvent. From the abovementioned salts of 2-(2-methoxyphenoxy)ethylamine, for example, hydrogenchloride, hydrogenbromide, hydrogentartrate, hydrogenoxalate or hydrogensulphate can be used, preferably 2-(2-methoxyphenoxy)ethylamine hydrogenchloride monohydrate (IV) in an amount of 2 to 5 equivalents, based on the starting carbazole (II). The reaction is carried out in the presence of 2 to 5 equivalents of a base, which is an alkali metal or alkaline earth metal carbonate, in an organic solvent, which is an alcohol having the number of carbons C2 to C5, preferably in the presence of anhydrous potassium carbonate in isopropanol. After

the reaction is finished, the solids are removed from the reaction mixture by filtration or centrifugation between the temperatures of 20 to 50 °C, the liquid portion is concentrated to 1/10 of the initial volume, the residue is diluted under heating in ethylacetate in the ratio 1:1 to 1:5, cooled to a temperature between 25 to 40 °C and after precipitating the crystal, the mixture is cooled to a temperature between 0 to 10 °C, the precipitated Carvedilol being isolated by filtration or centrifugation and further purified by crystallisation.

In comparison with other known methods, the method of production of Carvedilol of this invention is more advantageous in that a salt of 2-(2-methoxyphenoxy)ethylamine is used, which is, in comparison with the base, more stable and more available and it does not bring higher technical and economic requirements for the industrial realisation of the production of Carvedilol.

A surprising and new fact in the inventive method of production is that the method is advantageous in obtaining crude Carvedilol having up to three times lower contents of the bis-derivative than using existing known methods.

The method of preparation of Carvedilol of this invention is also advantageous in that the new conditions of the preparation in combination with purification and isolation of the substance increase the yield of the product and its purity and guarantee reliability of the production of an acceptable substance in required pharmacopoeial quality and with a defined particle size.

Methods of production of this invention will be clear from the following examples, which, however, do not limit the same in any case.

Examples

Example 1.

To a mixture of 5.0 kg anhydrous potassium carbonate and 7.5 kg of 2-(2-methoxyphenoxy)ethylamine hydrogenchloride monohydrate (IV) in 32 litres of isopropanol, mixed at a temperature of 35 °C for 15 min., are added 3.87 kg of 4-(oxirane-2-ylmethoxy)-9H-carbazole (II) and the mixture is, with intensive stirring,

heated at 83 °C for 5 hours. After the epoxide has reacted, the reaction mixture is filtered, isopropanol is distilled off and the residue is diluted in 20 l ethylacetate. The obtained solution is cooled, inoculated and stirred at the temperature of 35 °C for 30 minutes. After the crystal precipitates, the mixture is cooled to 5 °C and stirred for four hours. The crystallised raw Carvedilol is centrifuged and washed with cooled ethylacetate (HPLC contents > 98 area %, HPLC contents of the bis-derivative 1.2-1.5 area %).

The moist, crude Carvedilol is diluted at a temperature of 55 to 65 °C in 30 l ethylacetate, 0.8 kg of activated carbon is added, and stirred for 30 minutes at a temperature of 65 to 72 °C. Then the mixture is filtered, cooled to a temperature of 45 to 55 °C and it is stirred. After the crystal precipitates, the mixture is cooled to a temperature of 0 to 10 °C and is further stirred for four hours. The crystallised, purified Carvedilol is centrifuged, washed with cooled ethylacetate and dried at the temperature of 40 °C.

The purified Carvedilol is re-crystallised by the same method from 23 litres of ethylacetate. After drying at the temperature of 40 °C the Carvedilol substance is obtained in 45 % yield, of pharmacopoeial quality and of defined particle size.

Example 2.

A mixture of 9.7 g 4-(oxirane-2-ylmethoxy)-9H-carbazole (II), 53.7 g of anhydrous hydrogen sulphate of 2-(2-methoxyphenoxy)ethylamine (III) and 28 g of anhydrous potassium carbonate in 200 ml isopropanol are, with intensive stirring, heated at 80 °C for six hours. When the epoxide has reacted, the mixed salts are filtered off from the reaction mixture and isopropanol is distilled off from the filtrate. The obtained honey-like concentrate is diluted with heating in 50 ml of ethylacetate, the solution is cooled to the temperature of 40 °C, it is inoculated and stirred at the temperature of 40 °C for two hours. After the crystal precipitates, the mixture is cooled to the temperature of 0 °C, and is kept like that with stirring for a minimum of four hours. After filtration and washing with cooled ethylacetate, 5.2 g of wet, crude Carvedilol is obtained (HPLC contents 95.2 area %, HPLC contents of the bis-derivative 2.8 area %).

Example 3.

A mixture of 43.2 g 4-(oxirane-2-ylmethoxy)-9H-carbazole (II), 80.0 g of 2-(2-methoxyphenoxy)ethylamine hydrochloride monohydrate (IV) and 52.4 g of anhydrous calcium carbonate in 330 ml isopropanol is, with intensive stirring, heated at 80 °C for 4 hours. When the epoxide has reacted, the mixed salts are filtered off from the reaction mixture and isopropanol is distilled off from the filtrate. The obtained honey-like concentrate is dissolved, when hot, in 210 ml of ethylacetate, the solution is cooled to the temperature of 40 °C, inoculated and stirred at the temperature of 40 °C for 30 minutes. After the crystal precipitates, the mixture is cooled to 0 °C, and is kept like that with stirring for a minimum of four hours. After filtration and washing with cooled ethylacetate, 65 to 70 g of wet crude Carvedilol is obtained (HPLC contents > 98 area %, HPLC contents of the bis-derivative 1.2-1.5 area %).

Example 4.

To a mixture of 245.2 g of anhydrous potassium carbonate and 374.5 g of 2-(2-methoxyphenoxy)ethylamine hydrochloride monohydrate (IV) in 1000 ml of isoamyl alcohol, stirred at the temperature of 80 °C, are added, in four portions during 5 hours, a total of 202.1 g of 4-(oxirane-2-ylmethoxy)-9H-carbazole (II). After adding the whole amount the reaction mixture is stirred for two further hours at a temperature of 80 to 85 °C. When the epoxide has reacted the mixed salts are filtered off from the reaction mixture and isoamyl alcohol is distilled off from the filtrate. A honey-like concentrate is, when hot, dissolved in 1000 ml of ethylacetate, the solution is cooled to the temperature of 30 °C, inoculated, and stirred for 30 minutes. After the crystal precipitates, the mixture is cooled to 0 °C and stirred for 5 hours. The crystallised crude Carvedilol is filtered off and washed with cooled ethylacetate.

The wet crude Carvedilol is dissolved while hot in 1000 ml of ethylacetate, activated carbon is added and the mixture is stirred for a further 30 minutes. Then

the mixture is filtered through diatomaceous earth and the filter is washed with 500 ml of hot ethylacetate. The filtrate is cooled to the temperature of 45 °C and stirred for 30 minutes, then it is cooled down to the temperature of 5 °C and stirred for 4 hours. The crystallised, purified Carvedilol is filtered off, washed with cooled ethylacetate and dried.

The obtained, purified Carvedilol is recrystallised from 1000 ml ethylacetate, the crystallised Carvedilol substance is centrifuged, washed with cooled ethylacetate and dried at the temperature of 40 °C in a vacuum drier, product being obtained in 41% yield.

Industrial Applicability

This invention can be used in the pharmaceutical industry for the production of Carvedilol, which is used in medical practice as a combined alpha- and betalytic with vasodilating activity.

C L A I M S

1. A method of preparation of Carvedilol, characterized in that 4-(oxirane-2-ylmethoxy)-9H-carbazole is reacted with a salt of 2-(2-methoxyphenoxy)-ethylamine in an amount of 2.0 to 5.0 equivalents with respect to the starting carbazole, whereas the said salt can contain 0 to 10 % water, in the presence of a base, which is an alkali metal or alkaline earth metal carbonate, which is added in an amount of 2.0 to 5.0 equivalents with respect to the starting carbazole, and in a solvent from the group of alcohols having the number of carbons C2 to C5, at an elevated temperature, whereas, after completion of the reaction, Carvedilol is obtained from the reaction mixture.
2. The method of claim 1 characterized in that the solvent is an alcohol having the number of carbons C2 to C5, preferably isopropanol.
3. The method of claim 1 characterized in that the base is preferably potassium carbonate or calcium carbonate.
4. The method of claim 1 characterized in that the reaction temperature is maintained in the range of 75 to 85 °C.
5. The method of claim 1 characterized in that, after completion of the reaction, the reaction mixture is depleted of solids, the liquid portion is concentrated, the residue is dissolved in an organic solvent, cooled down and crystallized to give crude Carvedilol, which is separated and re-crystallized.
6. The method of claim 5 characterized in that the solids are separated by filtration or centrifuging within the temperature range of 20 to 50 °C.
7. The method of claim 5 characterized in that the liquid portion is concentrated to 1/10 of the initial volume, the concentrate is dissolved in ethylacetate in a ratio

1:1 to 1:5, cooled down to a temperature 25 to 40 °C and after the crystal falls out the mixture is cooled down to a temperature 0 to 10 °C, carvedilol being isolated by filtration or centrifuging.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/SK 03/00020

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D209/88

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | US 4 503 067 A (DIETMANN KARL ET AL) 5 March 1985 (1985-03-05) cited in the application column 5, line 55 - line 66 & DE 28 15 926 A 18 October 1979 (1979-10-18) cited in the application | 1 |
| A | EP 0 127 099 A (BOEHRINGER MANNHEIM GMBH) 5 December 1984 (1984-12-05) examples 7,8 | 1 |
| A | WO 02 00216 A (DOLITZKY BEN ZION; TEVA PHARMA (IL); ARONHIME JUDITH (IL); HILDESH) 3 January 2002 (2002-01-03) cited in the application examples 1,2 | 1 |
| | — —/— — | |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

17 February 2004

Date of mailing of the international search report

25/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/SK 03/00020

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | <p>EP 0 918 055 A (EGIS GYOGYSZERGYAR RT.) 26 May 1999 (1999-05-26) cited in the application examples 3,4,9,10 -----</p> | 1 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/SK 03/00020

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| US 4503067 | A | 05-03-1985 | DE 2815926 A1 | 18-10-1979 |
| | | | AT 375639 B | 27-08-1984 |
| | | | AT 276279 A | 15-01-1984 |
| | | | AU 522975 B2 | 08-07-1982 |
| | | | AU 4582079 A | 18-10-1979 |
| | | | BG 61419 B2 | 31-07-1997 |
| | | | CA 1129416 A1 | 10-08-1982 |
| | | | CS 227007 B2 | 16-04-1984 |
| | | | CS 9104200 A3 | 15-04-1992 |
| | | | CS 227047 B2 | 16-04-1984 |
| | | | DD 143607 A5 | 03-09-1980 |
| | | | DE 2960553 D1 | 05-11-1981 |
| | | | DK 141979 A ,B, | 14-10-1979 |
| | | | EP 0004920 A1 | 31-10-1979 |
| | | | ES 479396 A1 | 16-04-1980 |
| | | | FI 791142 A ,B, | 14-10-1979 |
| | | | HK 2385 A | 18-01-1985 |
| | | | HU 179433 B | 28-10-1982 |
| | | | IL 57020 A | 30-07-1982 |
| | | | JP 1023462 B | 02-05-1989 |
| | | | JP 1545837 C | 28-02-1990 |
| | | | JP 54157558 A | 12-12-1979 |
| | | | JP 63258416 A | 25-10-1988 |
| | | | LT 2628 R3 | 25-04-1994 |
| | | | LU 88320 A9 | 04-05-1994 |
| | | | LV 5234 A3 | 10-10-1993 |
| | | | MX 9203380 A1 | 01-09-1992 |
| | | | SG 52284 G | 29-03-1985 |
| | | | SU 810079 A3 | 28-02-1981 |
| | | | ZA 7901732 A | 28-05-1980 |
| EP 0127099 | A | 05-12-1984 | DE 3319027 A1 | 29-11-1984 |
| | | | AT 27273 T | 15-06-1987 |
| | | | AU 551116 B2 | 17-04-1986 |
| | | | AU 2848084 A | 29-11-1984 |
| | | | CA 1259071 A1 | 05-09-1989 |
| | | | CA 1257279 A2 | 11-07-1989 |
| | | | DE 3463768 D1 | 25-06-1987 |
| | | | DK 91393 A | 06-08-1993 |
| | | | DK 255184 A | 27-11-1984 |
| | | | EP 0127099 A1 | 05-12-1984 |
| | | | ES 8502683 A1 | 16-04-1985 |
| | | | FI 842046 A ,B, | 27-11-1984 |
| | | | GR 81577 A1 | 11-12-1984 |
| | | | HU 34160 A2 | 28-02-1985 |
| | | | IE 57533 B1 | 24-03-1993 |
| | | | IL 71876 A | 30-10-1987 |
| | | | JP 1818634 C | 27-01-1994 |
| | | | JP 5027622 B | 21-04-1993 |
| | | | JP 59222473 A | 14-12-1984 |
| | | | JP 1917129 C | 23-03-1995 |
| | | | JP 5208957 A | 20-08-1993 |
| | | | JP 6013508 B | 23-02-1994 |
| | | | KR 8601761 B1 | 21-10-1986 |
| | | | NO 842084 A ,B, | 27-11-1984 |
| | | | NZ 208254 A | 29-11-1988 |
| | | | PH 22749 A | 28-11-1988 |
| | | | PT 78633 A ,B | 01-06-1984 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/SK 03/00020

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP 0127099 | A | US 4824963 A | 25-04-1989 |
| | | US 4985454 A | 15-01-1991 |
| | | US 4697022 A | 29-09-1987 |
| | | US 5071868 A | 10-12-1991 |
| | | ZA 8403976 A | 30-01-1985 |
| WO 0200216 | A | 03-01-2002 | |
| | | AU 7163901 A | 08-01-2002 |
| | | CA 2413702 A1 | 03-01-2002 |
| | | CN 1449286 T | 15-10-2003 |
| | | EP 1299101 A1 | 09-04-2003 |
| | | HU 0301802 A2 | 29-09-2003 |
| | | JP 2004501191 T | 15-01-2004 |
| | | SK 862003 A3 | 03-06-2003 |
| | | WO 0200216 A1 | 03-01-2002 |
| EP 0918055 | A | 26-05-1999 | |
| | | HU 9802180 A1 | 28-12-2000 |
| | | CZ 9803561 A3 | 16-06-1999 |
| | | DE 69813729 D1 | 28-05-2003 |
| | | DE 69813729 T2 | 05-02-2004 |
| | | EP 1142873 A2 | 10-10-2001 |
| | | EP 1142874 A2 | 10-10-2001 |
| | | EP 0918055 A1 | 26-05-1999 |
| | | ES 2196459 T3 | 16-12-2003 |
| | | HR 980590 A1 | 31-10-1999 |
| | | PL 329828 A1 | 07-06-1999 |
| | | SI 918055 T1 | 31-12-2003 |
| | | SK 156098 A3 | 11-06-1999 |